THERANOSTICS 2016* , ,
Presentations this author is a contributor to:
68Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors – a head-to-head comparison with DOTATOC and FDG PET/CT (#15)
4:00 PM
Michael Lassmann
Optimising Peptide Receptor Radionuclide Therapy (PRRT) - (submitted abstracts)
Phase I/II open-label trial to evaluate the safety and preliminary efficacy of 177Lu-OPS201, a radiolabeled somatostatin receptor antagonist, in patients with somatostatin receptor-positive, progressive gastroenteropancreatic neuroendocrine tumors (#57)
8:30 AM
Rod Hicks
Conference Breakfast: Moderated Poster Walk - Neuroendocrine tumours